Interest in central neurokinin (NK) 1 receptors has increased based on reports of the therapeutic potential for NK1 antagonists in anxiety and depression. In these studies, an ex vivo binding procedure was used to correlate NK1 receptor occupancy in striatum by NK1 antagonists with their potency to inhibit NK1 agonist-induced foot tapping in gerbils (GFT). The following compounds were administered orally: I-substance P binding by NK1 antagonists were compared with the corresponding EC 50 values for inhibition of GFT, a significant positive correlation was observed (r 2 ϭ 0.97, p Ͻ 0.001). This result indicates that increased NK1 receptor occupancy in striatum by NK1 antagonists parallels the inhibition of agonist-mediated GFT. For all compounds, the dose that produced the maximum inhibition of GFT resulted in less than 100% ex vivo receptor occupancy in striatum. When gerbils did not receive the i.c.v. saline injection before ex vivo binding, thereby leaving the blood-brain barrier (BBB) intact, the IC 50 values for antagonists were unchanged, suggesting that potential damage to the BBB caused by the i.c.v. injection did not affect determinations of antagonist potency in the GFT model.
phenyl]methoxy)-2-phenylpiperidine]. Two hours later, gerbils received the NK1 agonist GR73632 [H 2 N-(CH 2 ) 4 -CO-Phe-Pro-NMe-Leu-Met-NH 2 ] i.c.v. and foot tapping was measured for 5 min. The same procedure was used for ex vivo binding studies except that saline, rather than agonist, was administered i.c.v. before dissection of the striatum. The tissue homogenate was then used in an equilibrium radioligand binding assay. When IC 50 values for inhibition of ex vivo 125 I-substance P binding by NK1 antagonists were compared with the corresponding EC 50 values for inhibition of GFT, a significant positive correlation was observed (r 2 ϭ 0.97, p Ͻ 0.001). This result indicates that increased NK1 receptor occupancy in striatum by NK1 antagonists parallels the inhibition of agonist-mediated GFT. For all compounds, the dose that produced the maximum inhibition of GFT resulted in less than 100% ex vivo receptor occupancy in striatum. When gerbils did not receive the i.c.v. saline injection before ex vivo binding, thereby leaving the blood-brain barrier (BBB) intact, the IC 50 values for antagonists were unchanged, suggesting that potential damage to the BBB caused by the i.c.v. injection did not affect determinations of antagonist potency in the GFT model.
The neurokinin (NK) 1 receptor is a member of the tachykinin receptor family of G protein-coupled receptors. The endogenous peptide substance P (SP) binds with greater affinity to the NK1 receptor compared with the NK2 and NK3 receptor subtypes (Saria, 1999) . It is localized in high concentrations within the CNS, particularly in the striatum, amygdala, and some hypothalamic and thalamic nuclei in gerbils (Shults et al., 1982) , rats (Kiyama and Maeno, 1998) , and humans (Stout et al., 2001) .
There is evidence that NK1 receptor activation may be linked to depression and anxiety. NK1 receptors are localized in limbic structures containing monoaminergic neurons, which are thought to be the targets of both traditional monoamine oxidase inhibitors and tricyclic antidepressants, as well as the newer reuptake inhibitors. In addition, central administration of SP produces behavioral effects that mimic stress responses, including anxiogenesis in rats and vocalizations in guinea pigs (Stout et al., 2001) . The discovery of nonpeptide NK1 antagonists (McLean, 1996) has led to their development as potential therapeutic agents for the treatment of anxiety and depression (Kramer et al., 1998) , as well as emesis (Rupniak and Kramer, 1999; Diemunsch and Grelot, 2000) .
Species differences in the affinity of nonpeptide NK1 antagonists for the NK1 receptor have been reported (Beresford ABBREVIATIONS: NK, neurokinin; SP, substance P; CNS, central nervous system; GFT, gerbil foot tapping; BBB, blood-brain barrier; GR73632, H 2 N-(CH 2 ) 4 -CO-Phe-Pro-NMe-Leu-Met-NH 2 ; CP-99,994, (ϩ)-cis-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine; L-742,694, 5-[[2(S)-[[3,5-bis(trifluoromethyl) 2, 721, 2,3-triazole-5-methanamine; GR205171, N-[[2-methoxy-5-[5-(trifluoromethyl) Snider et al., 1991; Fong et al., 1992) . The affinity of nonpeptide NK1 antagonists for both the gerbil and guinea pig NK1 receptor is very similar to that for the human NK1 receptor (Saria, 1999) . Due to the low affinity for the rat and mouse NK1 receptor, rodent behavioral models of depression and anxiety are not routinely used to study the pharmacology of NK1 antagonists. Alternative behavioral models have used gerbils and guinea pigs to study nonpeptide NK1 antagonist pharmacology. These include locomotor activity (McLean et al., 1993 (McLean et al., , 1996 in guinea pigs, as well as both isolationinduced (Kramer et al., 1998; Boyce et al., 2001 ) and NK1 agonist-induced vocalizations in guinea pigs (Rupniak et al., 2000) .
Another alternative animal model commonly used to study NK1 antagonist potency measures rhythmic hind foot tapping in the Mongolian gerbil (GFT). This behavior has been described as a natural warning response (Bristow and Young, 1994) , and in a more recent study examining shockinduced foot tapping in gerbils, the authors report that GFT is an expression of fear or anxiety that can be reversed by anxiolytics (Ballard et al., 2001) . GFT can also be induced by i.c.v. NK1 agonist administration (Rupniak and Williams, 1994) . Nonpeptide NK1 antagonists have been reported to potently inhibit this response (Rupniak et al., 1997; Kramer et al., 1998) , which is believed to be the result of direct blockade of NK1 receptors.
In these studies, we used an ex vivo radioligand binding procedure to measure the occupancy of NK1 antagonists to the NK1 receptor in gerbil brain. Ex vivo binding studies have previously been used to demonstrate brain penetration of NK1 antagonists (Beattie et al., 1995; Iyengar et al., 1997) . For these studies, drugs were administered to intact animals, the tissues of interest extracted, and a competitive binding assay performed with the treated tissue homogenates. The purpose of these studies was to determine whether NK1 receptor occupancy in gerbil striatum by NK1 antagonists correlates with inhibition of GFT at similar doses. The brain regions selected for these studies have been associated with changes in NK1 receptors in response to both agonist binding and stress (Mantyh et al., 1995; Smith et al., 1999) .
We also assessed whether the GFT model is an accurate determinant of brain penetration of some NK1 antagonists. In the GFT model, where the agonist is administered i.c.v., the BBB could potentially be compromised. There are studies reporting leakage of non-CNS-penetrant compounds into the periphery after i.c.v. administration (Anderson et al., 1977; Maccarrone et al., 1983; Kujacic and Carlsson, 1994) . It is conceivable that a compound administered peripherally could leak into the CNS through a needle puncture in the BBB caused by the i.c.v. injection, thereby giving an overestimate of its potency. For these ex vivo studies, we administered saline i.c.v. to simulate the procedure in the GFT studies, where the NK1 agonist is administered i.c.v. By comparing striatal NK1 receptor occupancy in sham i.c.v.-injected animals with that found for separate groups of noninjected gerbils, we were able to assess whether any potential damage to the BBB after i.c.v. agonist injection in the GFT model could effect subsequent determinations of in vivo potency.
Experimental Procedures Materials
Female Mongolian gerbils (30 -40 g) were purchased from Charles River Laboratories (Kingston, NY). The following compounds were synthesized at the Schering-Plough Research Institute (Kenilworth, NJ): CP-99,994 (McLean et al., 1993) ; CP-122,721 (McLean et al., 1996) ; L-742,694 (Rupniak et al., 1997) ; MK-869 (Kramer et al., 1998) ; the para-fluoro derivative of L-760,735, herein referred to as L-760,735-F (compound 3 in Harrison et al., 2001) ; and GR205171 (Gardner et al., 1996) . The remaining compounds were purchased from Sigma/RBI (Natick, MA): L-733,060 (Rupniak et al., 2000) ; L-733,061; and GR73632. Bolton Hunter 125 I-SP was purchased from PerkinElmer Life Sciences (Boston, MA). Protein determinations were made using the BCA reagent kit (Pierce Chemical, Rockford, IL).
Procedure
In Vitro Homogenate Binding Studies. Gerbils were sacrificed under CO 2 anesthesia and the striatum dissected, weighed, and homogenized in 20 volumes of 50 mM Tris-HCl, pH 7.4 (buffer A). The homogenate was centrifuged at 40,000g for 30 min, and the pellet was resuspended in buffer A. The homogenate was again centrifuged as described above and resuspended in buffer A containing protease inhibitors (Complete brand; Roche Applied Science, Indianapolis, IN) and frozen at Ϫ80°C until use.
Competition binding assays were performed by incubating membranes (20 g of pro) with Bolton Hunter-labeled 125 I-SP, at a concentration of 0.1 nM, and concentrations of drug ranging from 0.0001 to 3 M in buffer A containing 3 mM MnCl 2 , 1 mM MgCl 2 , and 0.3% bovine serum albumin and protease inhibitors (buffer B). For saturation studies, concentrations of 125 I-SP ranging from 2 to 1000 pM were incubated with membranes. Nonspecific binding was defined in the presence of 1 M CP-99,994. Assays were terminated by rapid filtration onto 0.5% polyethylenamine-treated GF/C filter plates (Packard Instrument Co., Meriden, CT) using a Tomtec cell harvester (PerkinElmer Wallac, Boston, MA). The plates were dried and Microscint scintillation cocktail (Packard Instrument Co.) was added, after which the bound radioactivity was quantified using a TopCount scintillation counter (Packard Instrument Co.).
For the in vitro binding studies, the dissociation constant (K d ) of 125 I-SP in gerbil striatal membranes was determined by plotting specific binding at each concentration of radioligand, and analysis by nonlinear regression (GraphPad Prism; GraphPad Software, San Diego, CA). For competition studies, the IC 50 for each drug to inhibit the binding of 125 I-SP was determined by nonlinear regression analysis of the radioligand displacement curves. Affinity constants (K i ) were calculated using the equation derived by Cheng and Prusoff (1973) .
Ex Vivo Homogenate Binding Studies. All studies were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were conducted at Association for Assessment and Accreditation of Laboratory Animal Care-accredited facilities under guidelines established by the Schering-Plough Animal Care and Use Committee. Gerbils were injected with test compounds orally at doses of 0.003, 0.03, 0.3, 3, and 30 mg/kg in a volume of 5 ml/kg, with three animals in each treatment group, including a vehicle control. Two hours later, each gerbil was anesthetized by inhalation of an oxygen/isofluorane mixture (Ohmeda, West Yorkshire, UK) using a VMC anesthesia machine (Matrx Medical, Orchard Park, NY), after which the skull was exposed, and a 5-l injection of saline was given i.c.v., using bregma as the guide, at a depth of 4.5 mm. The sham i.c.v. injection was administered to simulate the procedure used in the GFT assay (see below). Five minutes after the i.c.v. saline injection the animals were sacrificed, by CO 2 inhalation and decapitation, and the brains dissected. jpet.aspetjournals.org administered to groups of gerbils (n ϭ 3) and, at each of four time points (2, 6, 24, and 48 h), a sham i.c.v. injection of saline was administered as described above to one vehicle and one treated group. Unless otherwise stated, results reported are for gerbils receiving a saline i.c.v. injection before sacrifice.
In a separate group of studies to examine the effects of the i.c.v. injection on measures of ex vivo potency, animals received only antagonists orally as described above. These animals did not receive any anesthesia or have any surgical procedure or i.c.v. injection. The tissues were collected as described above. The results of these studies will be noted as nonsham i.c.v.-injected animals.
For all ex vivo homogenate binding studies, the striatum was dissected and homogenized in 10 ml of buffer A using a hand-held Tissue Tearor homogenizer (Biospec, Racine, WI). Protein concentrations were determined using the BCA reagent kit, and the volume was adjusted so that the concentration of protein was 50 g/100 l. The homogenates were then incubated at 37°C for 15 min to remove endogenous substance P. Aliquots of the striatal homogenate from each animal in each treatment group were incubated with 0.2 nM Bolton-Hunter 125 I-SP in buffer B. Nonspecific binding was defined in the presence of 1 M CP-99,994. Assays were incubated for 40 min at room temperature then terminated by rapid filtration as described above. The plates were dried, scintillant added, and the bound radioactivity determined as described above.
Data were analyzed by subtracting nonspecific binding from each treated tissue then calculating the percentage of binding in the absence of drug (% control). Values for 50% inhibition of control binding (IC 50 ) were calculated by nonlinear regression analysis using GraphPad Prism analysis software.
Ex Vivo Autoradiography Studies. For autoradiography studies, the gerbils were treated as described above with either vehicle or drug, and 5 min after the i.c.v. saline injection, the whole brain was dissected and frozen at Ϫ80°C until use. The brains were mounted and 20-m coronal sections were serially cut using a Leica cryostat (Leica, Nussloch, Germany), thaw-mounted onto coated slides, and stored at Ϫ80°C until use. Representative sections for each treated animal were thawed to room temperature then preincubated at 37°C for 20 min in buffer A containing 0.3% bovine serum albumin. Sections were then incubated in buffer B containing 0.1 nM Bolton Hunter 125 I-SP. Nonspecific binding was defined in adjacent sections in the presence of 10 M CP-99,994. After washing the slides 4 ϫ 20 s in buffer A, the slides were dried and apposed to Biomax MR film (Eastman Kodak, Rochester, NY) for 2 days.
Analysis of the autoradiograms was carried out using a microcomputer imaging device from Imaging Research (St. Catherines, ON, Canada), where nonspecific binding in the amygdala from the adjacent serial section was subtracted from the relative optical density of the total bound for amygdala. The relative optical densities found in amygdala were then calculated for each dose of drug in sections from approximately the same rostral/caudal plane.
Behavioral Testing in GFT Model. Gerbils were anesthetized by inhalation of an oxygen/isofluorane mixture as described above. The tachykinin NK1 agonist GR73632 (3 pmol) was administered i.c.v. in a volume of 5 l using the same procedure as described above. Immediately after recovery of the righting reflex, gerbils were placed individually into clear Plexiglas boxes, and the duration of foot tapping was measured. Foot tapping was defined as rhythmic, repetitive tapping of the hind feet. The time spent foot tapping was recorded with a stopwatch in real time by the experimenter during a 5-min observation period. During dose-response drug studies, NK1 antagonists were administered orally 2 h before the NK1 agonist. For time course studies, vehicle and drug-treated groups were tested at each time point as described above. Data are expressed as a percentage of decrease (% inhibition) in the amount of time spent foot tapping compared with vehicle-treated animals. The dose that produced 50% inhibition of the vehicle response (EC 50 ) was calculated jpet.aspetjournals.org using nonlinear regression analysis with GraphPad Prism analysis software. The maximally effective dose (EC 90 ) was defined as the dose that inhibited GFT at 90% or greater.
Results
The chemical structures for the compounds used in these studies are shown in Fig. 1 . Table 1 The inset in Fig. 2a shows the ex vivo inhibition of 125 I-SP in striatal homogenates of gerbils pretreated with L-733,060 or its inactive enantiomer, L733,061. At doses as high as 30 mg/kg, no inhibition with L733,061 was found, indicating that the inhibition produced in striatum by these compounds is stereoselective. L-733,061 did not inhibit agonist-induced GFT at doses of 30 mg/kg (data not shown). Receptor occupancy for each antagonist at the maximally effective dose to inhibit GFT, shown in Table 1 as EC 90 , was estimated from the ex vivo binding curves. The behaviorally active dose for each antagonist was first extrapolated from the x-axis of the corresponding ex vivo binding graph to the intercept point of the ex vivo inhibition curve. The percentage of inhibition of 125 I-SP binding at that intercept point was then calculated, giving an estimate of the percentage of receptors occupied at the EC 90 dose, which is shown in Table 1 .
A time course of the GFT response in the presence of 1 mg/kg MK-869 is compared with the time course of ex vivo 125 I-SP binding in Fig. 3 . MK-869 produced significant inhibition of foot tapping when administered as long as 24 h before testing. Forty-eight hours post-treatment, no behavioral inhibition of GFT was observed. Similarly, NK1 receptor binding of 125 I-SP was inhibited up to 24 h after MK-869 treatment, with little inhibition at 48 h. Figure 4 shows the correlation of the IC 50 for inhibition of ex vivo 125 I-SP binding in gerbil striatum with the EC 50 for inhibition of the GFT response in gerbil. A significant positive Spearman correlation coefficient was found (r 2 ϭ 0.97, p Ͻ0.001) between these two measures, indicating that doses of NK1 antagonists that produce behavioral effects are associated with those that inhibit the binding of 125 I-SP in gerbil striatum. Figure 5 shows the results of ex vivo autoradiography of the inhibition of 125 I-SP in gerbil brain after MK-869 administration at a 2-h pretreatment. Increasing concentrations of MK-869 inhibited binding of 125 I-SP in regions high in NK1 receptors, including the striatum and amygdala. The relative optical densities calculated for amygdala from these studies are shown in Fig. 5b . Table 2 shows the comparison of IC 50 values for the inhibition of ex vivo 125 I-SP binding in striatum in groups of gerbils receiving a saline i.c.v. injection (sham) 2 h after antagonist administration with those that received antagonist alone with no i.c.v. injection (nonsham). For each compound, the percentage of control for sham versus nonsham at each concentration was compared using a post hoc t test. No significant differences were found for any compound tested (p Ͼ 0.05, Tukey's post hoc test).
Discussion
In these studies, an ex vivo binding procedure was used to measure receptor occupancy in gerbil brain. Gerbils were pretreated orally with NK1 antagonists and competitive radioligand binding in striatal homogenates was measured ex vivo. The aim of these studies was to correlate NK1 receptor occupancy with the behavioral effects of NK1 antagonists in the GFT model. These antagonists have been reported to be highly selective for the NK1 receptor compared with the NK2 and NK3 receptor subtypes. The in vitro binding affinities reported herein for the gerbil NK1 receptor agree with published values at the human NK1 receptor (McLean et al., 1993; Gardner et al., 1996; McLean et al., 1996; Rupniak et al., 1997 Rupniak et al., , 2000 Kramer et al., 1998; Harrison et al., 2001 ). The concentration of 125 I-SP used in these studies approximates its affinity constant (K d ) for the NK1 receptor. In addition, Bolton Hunter-labeled SP has been shown to be highly selective for the NK1 subtype (Mussap et al., 1993) , and therefore binding of the radioligand to other neurokinin receptor subtypes is unlikely. This suggests that the ex vivo binding potency being measured was to the NK1 receptor subtype.
Orally administered NK1 antagonists dose-dependently inhibited ex vivo 125 I-SP binding in gerbil striatal homogenates in a manner that was both stereoselective and timedependent. L-733,060 potently inhibited both ex vivo 125 I-SP binding and GFT, whereas its inactive enantiomer L-733,061 neither displaced 125 I-SP ex vivo nor produced an inhibition of GFT. In time-course studies, both the inhibition of GFT and the ex vivo displacement of 125 I-SP by MK-869 were detected up to 24 h post-treatment, whereas neither effect persisted for 48 h. These data further suggest that this ex vivo binding procedure is measuring the binding of compounds to the NK1 receptor in gerbil striatum.
One concern regarding ex vivo homogenate binding studies is that the antagonist will dissociate from the receptor when diluted with buffer before homogenization. In these studies the homogenates were diluted less than 10-fold, however, which is insufficient to significantly dissociate the drug from the receptor. In addition, all of the tissues were diluted to an equivalent concentration, so displacement of the antagonist by dilution alone would not explain the dose-dependent inhibition seen in these studies.
Using the ex vivo autoradiographic procedure, we were able to measure the binding of NK1 antagonists to smaller brain regions. The amygdala was of particular interest because it has been associated with stress responses in many rodent species. NK1 antagonists have been shown to inhibit receptor internalization in amygdala after restraint-induced stress in guinea pigs (Smith et al., 1999) . Pretreating gerbils with MK-869 dose-dependently inhibited ex vivo 125 I-SP binding in the amygdala with a displacement parallel to that seen in striatum, suggesting that there are no regional differences in binding of NK1 antagonists between these two areas.
The relative potency of NK1 antagonists to inhibit ex vivo 125 I-SP binding did not correlate with their in vitro affinity for the NK1 receptor, but did mirror their potency to inhibit GFT. The mismatch between the in vitro affinity and either the ex vivo or GFT potency suggests that the differences observed between compounds are pharmacokinetic in nature, and reflect differences in oral bioavailability, metabolic stability, and/or BBB penetrability.
The main objective of these studies was to determine a correlation between a behavioral measure and a receptor Using a robust and well characterized behavioral effect (GFT), elicited by NK1 agonist administration, these studies demonstrate a significant positive correlation between the inhibition of GFT in the gerbil by NK1 antagonists and NK1 receptor occupancy in striatum. The relative potency for the antagonists to inhibit ex vivo 125 I-SP binding was similar to their in vivo potency to inhibit GFT. Because the GFT response is elicited by NK1 receptor activation, it suggests that the inhibition of the response must also be mediated through NK1 receptor blockade. These studies support the concept that NK1 receptor occupancy by NK1 antagonists is associated with the inhibition of the GFT behavioral response.
A recent study has suggested that shock-induced GFT may be a measure of anxiety in gerbils that can be reversed by both the NK1 antagonist MK-869 and the anxiolytic diazepam, but not by the antidepressant fluoxetine (Ballard et al., 2001 ). In Ballard's study, GFT was induced by a series of cued foot shocks. In our study, GFT was pharmacologically induced by NK1 agonist administration. It is unclear whether a parallel can be drawn between the conclusions of these two studies. Central SP administration has been shown to produce anxiogenic behaviors in both rats and guinea pigs (Stout et al., 2001) , and it could be argued that NK1 agonist administration produces an anxiogenic response in gerbils that is manifested as GFT. However, most researchers have used the GFT model to study NK1 antagonist efficacy, and little work has been done to validate the NK1 agonist-induced GFT model as an efficacy model for anxiety or depression.
From these studies, estimates of NK1 receptor occupancy were determined for behaviorally active doses of NK1 antagonists. At doses that produce maximal inhibition of the GFT response, all of the antagonists tested exhibit between 40 and 90% NK1 receptor occupancy in striatum. These estimates agree with the range of receptor occupancies reported for other neurotransmitter systems. For antipsychotic drug-induced behaviors thought to be mediated by 5HT2 and D2 receptors, occupancies of 10 to 80% have been reported Schotte et al., 1993) . A threshold effect of 60 to 70% D2 receptor occupancy in striatum has been reported to result in the induction of catalepsy (Crocker and Hemsley, 2001) .
The dose-response curves for ex vivo binding of antagonists were generally shifted to the right compared with the GFT potency curves, resulting in lower receptor occupancy. One possible explanation for this finding is that it reflects the presence of a higher concentration of agonist ( 125 I-SP) in the ex vivo binding studies compared with GR73632 at the synapse in the GFT model. A higher concentration of antagonist would be needed to compete with the agonist in the ex vivo binding studies, thereby shifting the dose-response curve to the right compared with the GFT.
A second explanation for less than 100% receptor occupancy at the maximum inhibition of GFT is the presence of spare NK1 receptors in striatum. Early studies in guinea pig ileum (Bergmann, 1983) and rat parotid gland (Gater et al., 1982) suggested the presence of spare NK1 receptors in response to the effects of SP on both contractile responses and amalyse activity. The findings described herein support earlier work that NK1 receptor reserves may be present in brain as well as in the periphery. Studies examining SP-induced NK1 receptor internalization in cells (Garland et al., 1996; McConalogue et al., 1999) found that up to 20% of receptors are not internalized, which suggests that there is a subpopulation of NK1 receptors that may not be responsive to ago- nist-mediated stimulation. Our studies suggest that only some fraction of receptors needs to be blocked to produce a robust inhibition of the GFT response. Another purpose of this study was to determine whether potentially compromising the BBB by injecting the agonist i.c.v. before measuring GFT overestimates the potency of peripherally administered NK1 antagonists. Penetrating the menigial layers with a needle may have an effect on the BBB. Although there is evidence that nonpenetrant compounds administered i.c.v. can diffuse from the CNS into the periphery (Anderson et al., 1977; Maccarrone et al., 1983; Kujacic and Carlsson, 1994) , it is often questioned whether an i.c.v. injection increases the brain penetration of peripherally administered compounds. We sought to answer this question by comparing receptor occupancy of NK1 antagonists in intact versus sham i.c.v.-injected gerbils. No significant differences in ex vivo binding potencies were found between saline i.c.v.-injected animals and intact animals, suggesting that the i.c.v. agonist injection does not increase the brain penetration of these peripherally administered NK1 antagonists and that the GFT model accurately determines their potency. The results of this study also suggest that the isofluorane/oxygen anesthetic administered to the gerbils before the i.c.v. injection does not affect the potency of test compounds, given that the noninjected gerbils in this study did not receive anesthesia.
The study reported herein suggests that NK1 receptor occupancy in striatum by NK1 antagonists is associated with inhibition of the GFT response in gerbils. This NK1 receptor occupancy is specific and mirrors the relative potency and time course of compounds to produce inhibition of the GFT. Finally, the ex vivo binding method described herein provides a means to quantitate receptor occupancy, and may have relevance to clinical dose ranging studies.
